Research highlights the challenges in treating renal medullary carcinoma (RMC), particularly in young athletes with sickle cell trait. Loss of the SMARCB1 gene renders standard anti-VEGF therapies and immune checkpoint inhibitors ineffective, prompting a call for clinical trials to explore alternative immunotherapy strategies.
Learn the warning signs of renal medullary carcinoma—sickle cell trait, right-sided mass—and why INI1 testing changes therapy and survival. The loss of SMARCB1 appears to protect RMC from anti-VEGF therapies, rendering drugs such as cabozantinib (Cabometyx), bevacizumab (Avastin), and lenvatinib (Lenvima) ineffective.8-10 Similarly, single-agent immunotherapy with pembrolizumab (Keytruda) and combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) are not only ineffective but may actually cause hyperprogression of the disease.11,12 · “Standard immune checkpoint therapy should be avoided for RMC outside of clinical trials,” Msaouel said, though he noted that ongoing trials are attempting to harness the immune system against RMC in different ways. Immunotherapy and targeted therapies directed against blood vessel growth have revolutionized treatment, offering hope even in advanced cases. But for a rare and aggressive kidney cancer known as renal medullary carcinoma (RMC), that same playbook can be dangerous. In fact, standard treatments may actually feed the disease. He added that there are patients with RMC around the world who have been cured of their disease thanks to the advice of their local oncology teams, even though his team has never met those patients in person. Msaouel’s message is one of urgency but also of hope. The correct diagnosis, made early, can change everything. For community oncologists who suspect RMC based on the clinical clues a young patient of African descent, a right sided kidney mass, sickle cell trait, a history of high intensity exercise, or an elevated CA 125 the next step is clear. At least 10% and up to 15% of patients with RMC can now be cured with current therapeutic strategies. “Our goal is to get this to 100%. These patients are young, and most are otherwise completely healthy. We really owe it to them to try hard to eradicate their disease.”
Original title: “The Hidden Kidney Cancer: A Rare Threat to Young Athletes | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways”